Pelago Bioscience Expands Drug Discovery Capabilities Through Acquisition of RG Discovery
Pelago Bioscience, a leading contract research organization (CRO) specializing in cell-based target engagement technologies, has announced the acquisition of RG Discovery, a Sweden-based drug discovery company recognized for its expertise in medicinal chemistry, custom synthesis, and integrated drug development services. The transaction marks a significant strategic expansion for Pelago Bioscience, enabling the company to offer a more comprehensive suite of drug discovery capabilities that combine advanced biological insights with world-class chemistry expertise.
The acquisition reflects a growing trend within the pharmaceutical and biotechnology industries toward integrated drug discovery models that bring together multiple scientific disciplines under a single organizational framework. By uniting Pelago Bioscience’s strengths in target engagement analysis with RG Discovery’s medicinal chemistry and compound design capabilities, the combined organization aims to provide researchers with a seamless platform that can support therapeutic development from early hit identification through lead optimization and candidate selection.
The newly expanded company believes the combination will help biotechnology firms, pharmaceutical companies, and academic drug discovery teams accelerate development timelines, improve decision-making, and reduce inefficiencies often associated with managing multiple external service providers.
Meeting the Evolving Demands of Modern Drug Discovery
Drug discovery has become increasingly complex over the past two decades. Researchers must navigate enormous volumes of biological data, rapidly evolving therapeutic targets, and increasingly sophisticated chemical design strategies while maintaining efficiency and controlling costs.
Traditionally, drug discovery programs often relied on multiple specialized service providers to perform different aspects of research. One organization might handle medicinal chemistry, another biological testing, and a third perform advanced mechanistic studies. While this approach can provide access to specialized expertise, it may also introduce delays, communication challenges, and workflow inefficiencies as projects move between different vendors.
As a result, many companies are seeking integrated research solutions that enable closer collaboration between chemistry and biology teams and facilitate faster iteration cycles during early-stage development.
Pelago Bioscience’s acquisition of RG Discovery is designed to address these evolving needs by bringing complementary capabilities together under one organizational structure.
According to Michael Dabrowski, Chief Executive Officer of Pelago Bioscience, the future of successful drug discovery depends on the seamless integration of biological and chemical sciences.
He explained that combining RG Discovery’s expertise with Pelago’s established target engagement platform creates a unique opportunity to support customers throughout critical stages of drug development. The integration allows compounds to be designed and synthesized, evaluated in living cells, and then rapidly refined based on biological feedback, creating a highly efficient cycle of continuous optimization.
Combining Chemistry and Biology in a Single Platform
One of the most significant advantages of the acquisition is the creation of a fully integrated discovery platform capable of connecting compound design directly with biological validation.
Pelago Bioscience has established itself as a leader in cell-based target engagement analysis through its proprietary Cellular Thermal Shift Assay (CETSA®) technology. CETSA enables scientists to directly measure whether and how a drug candidate interacts with its intended target inside living cells.
This capability provides highly valuable information because many compounds that perform well in laboratory assays fail to demonstrate effective target engagement within the complex environment of a living cell. Understanding these interactions early in development can help researchers identify promising candidates more efficiently and avoid costly failures later in the drug development process.
By integrating CETSA-generated biological insights with RG Discovery’s medicinal chemistry expertise, the combined organization can create a continuous feedback loop between chemistry and biology.
Researchers can design and synthesize new compounds, test their ability to engage biological targets in living cells, analyze the resulting data, and immediately use those findings to guide subsequent rounds of chemical optimization.
This iterative approach has the potential to accelerate lead generation and improve the quality of candidate molecules moving forward into preclinical development.
Closing the Gap Between Compound Design and Biological Validation
A common challenge in drug discovery involves the separation between chemistry-focused and biology-focused research organizations.
Chemistry CROs typically excel at designing and synthesizing molecules but may not provide advanced biological validation capabilities. Conversely, biology-focused organizations often generate valuable mechanistic insights but lack in-house medicinal chemistry resources to rapidly act on those findings.
Pelago believes the acquisition of RG Discovery addresses this gap by creating a unified workflow that eliminates many of the handoffs traditionally required between service providers.
The company notes that the integration effectively closes the loop between compound design, synthesis, and direct target engagement measurement in living cells. This reduces delays associated with transferring projects between vendors and enables scientists to make informed decisions more quickly.
The resulting workflow may help clients advance programs from hit identification to lead optimization with greater speed and confidence while maintaining a clear understanding of how candidate compounds behave in biologically relevant systems.
RG Discovery’s Established Reputation in Medicinal Chemistry
Founded in 2011 by former scientists from AstraZeneca, RG Discovery has developed a strong reputation for tackling challenging medicinal chemistry projects and supporting innovative drug discovery programs across the biotechnology and pharmaceutical sectors.
Over the years, the company has collaborated with a broad range of clients seeking expertise in custom synthesis, medicinal chemistry, structure-activity relationship studies, and integrated drug discovery services.
The organization currently employs approximately 40 scientists and operates from Medicon Village in Lund, Sweden, one of Scandinavia’s leading life science innovation hubs.
Its facilities include extensive chemistry laboratories and analytical infrastructure designed to support a wide variety of drug discovery activities. These capabilities have enabled RG Discovery to build a track record of solving complex scientific challenges and helping clients progress therapeutic programs efficiently.
The addition of these resources significantly expands Pelago Bioscience’s service offering and strengthens its position within the competitive contract research market.
Shared Scientific Vision Drives the Transaction
Leadership from both organizations emphasized the scientific alignment between the two companies as a key factor behind the acquisition.
Johan Evenäs, Chief Executive Officer and Co-founder of RG Discovery, noted that the company has always focused on helping clients address difficult scientific problems through close collaboration and technical excellence.
According to Evenäs, joining Pelago Bioscience creates an opportunity to extend that impact by combining advanced medicinal chemistry capabilities with cutting-edge target engagement science.
He highlighted the complementary nature of the two organizations and expressed enthusiasm about the opportunities the transaction creates for customers, employees, and future research collaborations.
The shared emphasis on scientific rigor, innovation, and customer-focused problem solving is expected to facilitate integration and support continued growth of the combined organization.
Strengthening Support for Pharmaceutical and Biotechnology Clients
The acquisition comes at a time when pharmaceutical and biotechnology companies face increasing pressure to improve research productivity while controlling development costs.
Bringing new therapies to market remains a lengthy and expensive process, with many drug candidates failing during early development due to insufficient efficacy, poor target engagement, or suboptimal pharmacological properties.
Integrated discovery platforms that combine medicinal chemistry and advanced biological analysis may help address these challenges by enabling more informed decision-making earlier in the development process.
For clients, the combined Pelago-RG Discovery platform offers access to a broader range of expertise through a single scientific partner. Rather than coordinating multiple vendors across different stages of research, organizations can potentially benefit from streamlined project management, improved communication, and faster scientific feedback.
The integrated model may be particularly valuable for emerging biotechnology companies that require flexible access to multidisciplinary expertise without building extensive internal infrastructure.
Expanding Opportunities in Integrated Drug Discovery
The pharmaceutical industry is increasingly recognizing the value of approaches that combine multiple scientific disciplines to accelerate innovation.
Advances in molecular biology, computational modeling, medicinal chemistry, and translational research have created new opportunities for integrated discovery strategies capable of identifying and optimizing therapeutic candidates more effectively.
Pelago Bioscience’s acquisition of RG Discovery positions the company to capitalize on this trend by offering a platform that connects compound design, synthesis, target engagement analysis, and biological validation within a unified workflow.
As drug discovery programs continue to become more sophisticated and data-driven, demand for such integrated solutions is expected to grow.
The acquisition represents an important milestone in Pelago Bioscience’s growth strategy and significantly broadens the company’s capabilities within the global drug discovery ecosystem.
By combining Pelago’s industry-leading CETSA-based target engagement technologies with RG Discovery’s medicinal chemistry and synthesis expertise, the organization has created a comprehensive platform designed to support therapeutic development from early discovery through lead optimization.
The integration is expected to provide customers with faster feedback cycles, more efficient workflows, and deeper scientific insights that can help accelerate the advancement of promising drug candidates.
As the combined company moves forward, it aims to leverage the strengths of both organizations to deliver a more connected and effective drug discovery experience, ultimately helping pharmaceutical and biotechnology innovators bring new therapies closer to patients in need.
About Pelago Bioscience
Pelago Bioscience is a drug discovery focused CRO, specializing in target engagement and target validation through its proprietary CETSA® technology platform. By measuring drug-target interactions directly in living cells and tissues, Pelago Bioscience helps pharmaceutical and biotechnology companies make more informed decisions throughout the drug discovery and development process. The company is headquartered in Stockholm, Sweden.
About RG Discovery
RG Discovery is an integrated drug discovery CRO headquartered in Lund, Sweden. The company provides medicinal chemistry, peptide chemistry, custom synthesis, ADME, bioanalysis, and related discovery services to biotechnology and pharmaceutical customers worldwide.
